Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Egeberg

Showing results (281-290 of 332) with videos related to

Pageof 34
Sort By:
JAMA Dermatology|August 17, 2022
Multivariable Predictive Models to Identify the Optimal Biologic Therapy for Treatment of Patients With Psoriasis at the Individual LevelMia-Louise Nielsen, Troels Christian Petersen, Julia-Tatjana Maul, et al.
American Journal of Clinical Dermatology|May 5, 2026
Correction to: Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-AnalysisAmalie Thorsti Møller Rønnstad, Daniel Isufi, Christopher G Bunick, et al.
JAMA Dermatology|April 6, 2022
Assessment of Frequency of Rosacea Subtypes in Patients With Rosacea: A Systematic Review and Meta-analysisYousef A Barakji, Amalie Thorsti Møller Rønnstad, Maria O Christensen, et al.
The Journal of Investigative Dermatology|April 29, 2023
Drug Survival of Adalimumab, Secukinumab, and Ustekinumab in Psoriasis as Determined by Either Dose Escalation or Drug Discontinuation during the First 3 Years of Treatment - a Nationwide Cohort StudyDavid Thein, Nana A L Rosenø, Julia-Tatjana Maul, et al.
American Journal of Clinical Dermatology|November 26, 2025
Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-AnalysisAmalie Thorsti Møller Rønnstad, Daniel Isufi, Christopher G Bunick, et al.
Scientific Reports|February 22, 2023
A fragment of type VI collagen alpha-6 chain is elevated in serum from patients with atopic dermatitis, psoriasis, hidradenitis suppurativa, systemic lupus erythematosus and melanomaSigne Holm Nielsen, Helena Port, Cecilie Møller Hausgaard, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|February 9, 2026
Patients With Chronic Urticaria Have Higher Health-Care Resource Utilisation: A Danish Nationwide Case-Control StudyJennifer Astrup Sørensen, Somaia Naassan, Christian Vestergaard, et al.
International Journal of Dermatology|August 7, 2024
Predictors of initiating biologics in the treatment of psoriasisEmilia Linnemann, Mia-Louise Nielsen, Lara Valeska Maul, et al.
Journal of the American Academy of Dermatology|July 17, 2017
Herpes zoster in psoriasis patients treated with tofacitinibKevin L Winthrop, Mark Lebwohl, Arnon D Cohen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 9, 2023
Freedom from disease in plaque psoriasis: Comparing the perceived importance of voting round 2 statements from a Delphi consensus of patients, physicians and nursesIlse van Ee, Elfie Deprez, Alexander Egeberg, et al.
Pageof 34

Showing results (281-290 of 332) with videos related to

Sort By:
Pageof 34
JAMA Dermatology|August 17, 2022
Multivariable Predictive Models to Identify the Optimal Biologic Therapy for Treatment of Patients With Psoriasis at the Individual LevelMia-Louise Nielsen, Troels Christian Petersen, Julia-Tatjana Maul, et al.
American Journal of Clinical Dermatology|May 5, 2026
Correction to: Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-AnalysisAmalie Thorsti Møller Rønnstad, Daniel Isufi, Christopher G Bunick, et al.
JAMA Dermatology|April 6, 2022
Assessment of Frequency of Rosacea Subtypes in Patients With Rosacea: A Systematic Review and Meta-analysisYousef A Barakji, Amalie Thorsti Møller Rønnstad, Maria O Christensen, et al.
The Journal of Investigative Dermatology|April 29, 2023
Drug Survival of Adalimumab, Secukinumab, and Ustekinumab in Psoriasis as Determined by Either Dose Escalation or Drug Discontinuation during the First 3 Years of Treatment - a Nationwide Cohort StudyDavid Thein, Nana A L Rosenø, Julia-Tatjana Maul, et al.
American Journal of Clinical Dermatology|November 26, 2025
Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-AnalysisAmalie Thorsti Møller Rønnstad, Daniel Isufi, Christopher G Bunick, et al.
Scientific Reports|February 22, 2023
A fragment of type VI collagen alpha-6 chain is elevated in serum from patients with atopic dermatitis, psoriasis, hidradenitis suppurativa, systemic lupus erythematosus and melanomaSigne Holm Nielsen, Helena Port, Cecilie Møller Hausgaard, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|February 9, 2026
Patients With Chronic Urticaria Have Higher Health-Care Resource Utilisation: A Danish Nationwide Case-Control StudyJennifer Astrup Sørensen, Somaia Naassan, Christian Vestergaard, et al.
International Journal of Dermatology|August 7, 2024
Predictors of initiating biologics in the treatment of psoriasisEmilia Linnemann, Mia-Louise Nielsen, Lara Valeska Maul, et al.
Journal of the American Academy of Dermatology|July 17, 2017
Herpes zoster in psoriasis patients treated with tofacitinibKevin L Winthrop, Mark Lebwohl, Arnon D Cohen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 9, 2023
Freedom from disease in plaque psoriasis: Comparing the perceived importance of voting round 2 statements from a Delphi consensus of patients, physicians and nursesIlse van Ee, Elfie Deprez, Alexander Egeberg, et al.
Pageof 34